Older adults taking GLP-1 receptor agonists, primarily semaglutide (Rybelsus, Ozempic, Wegovy), had a small uptick in their ...

A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

A combination treatment of semaglutide, trevogrumad and garetosmab causes fat loss and muscle growth in primate trials. Full ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...

A UK watchdog is urging women on GLP-1 weight-loss drugs like Ozempic and Mounjaro to use effective forms of birth control after receiving more than 40 pregnancy-related reports linked to the ...

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

A popular weight-loss drug may be changing how doctors treat obesity—but scientists are just starting to uncover exactly how ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Interim results from the Phase II COURAGE trial show that combining semaglutide with anti-GDF8 antibody trevogrumab preserves ...